Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
Key takeaways
- Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
- NXC-201 is a specialized CAR-T cell therapy designed to eliminate the source of toxic light chains in patients.
- To lead the upcoming regulatory and commercial phases, the company appointed Dr.
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? Maham Fatima Wed, May 6, 2026 at 12:05 AM GMT+7 2 min read IMMX Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins that cause organ failure. Topline results from the 40-patient study are expected in Q3 2026, which will be followed by a BLA submission and a planned commercial launch.
NXC-201 is a specialized CAR-T cell therapy designed to eliminate the source of toxic light chains in patients. The treatment has already received several high-priority regulatory labels, including Breakthrough Therapy and Orphan Drug designations from the FDA and EMA. If successful, it would become the first FDA-approved treatment specifically for the relapsed/refractory stage of this disease.
To lead the upcoming regulatory and commercial phases, the company appointed Dr. Richard Graydon as Chief Medical Officer. Dr. Graydon brings extensive experience from Merck and Johnson & Johnson, where he oversaw the approval of major oncology drugs like Keytruda and Darzalex. His expertise is expected to be vital as Immix Biopharma Inc. (NASDAQ:IMMX) transitions from a clinical-stage company to a commercial entity following the anticipated BLA filing.